Objectives. Somatic/psychiatric symptoms are frequently found in chronic pain patients (CPPs). The objectives of this study were to determine 1) which somatic/psychiatric symptoms are more commonly found in acute pain patients (APPs) and CPPs vs community nonpatients without pain (CNPWPs) and 2) if somatic/psychiatric symptom prevalence differs between APPs and CPPs. Design. The above groups were compared statistically for endorsement of 15 symptoms: fatigue, numbness/tingling, dizziness, difficulty opening/ closing mouth, muscle weakness, difficulty staying asleep, depression, muscle tightness, nervousness, irritability, memory, falling, nausea, concentration, and headaches.
Introduction
Comorbidity is defined as "any distinct clinical entity that has existed or may occur during a patient's clinical course who has the index disease under study" [1] . The concept of comorbidity is important because the presence of comorbid disease can often complicate, interfere with, or increase the difficulty of treatment of the index disease, thus making the prognosis worse [1] . Psychiatric comorbidity diagnosable on Axis I of the DSM is commonly found within chronic pain patients (CPPs) [2] . However, nonfibromyalgia (non-FMS) CPPs and FMS patients also commonly display comorbidities that can be described as somatic/psychiatric symptoms [3] [4] [5] [6] [7] . Some examples of these comorbidities are the following: sleep problems [8] , fatigue [4, 6, 9] , nonorganic physical findings [10] , headache [4, 5, 11] , irritable bowel symptoms [4, 6] , and restless leg symptoms [4, 12] .
Despite the above literature, little work has been done on determining if the prevalence of these somatic/psychiatric symptoms is actually greater in non-FMS CPPs vs appropriate controls. Two recent studies have indicated that this may be the case [13, 14] . In the first study, Grovle et al. [13] compared 466 patients with chronic sciatica to a general population sample for subjective health complaints and somatic symptoms. The prevalence of subjective health complaints such as headache, stomach discomfort, sleep problems, tiredness/fatigue, dizziness, anxiety, and depression was higher in the chronic sciatica group vs the general population sample [13] . In the second study, from a health plan claims database, chronic low back pain (CLBP) patients were compared with non-CLBP patients for comorbidity burden [14] . CLBP patients had a significantly greater prevalence of comorbid sleep problems, depression, and anxiety [14] .
The issue of prevalence of somatic/psychiatric symptoms in CPPs is important because of the apparent association between chronic pain and somatic/psychiatric symptoms. The risk of having chronic pain is increased strongly according to the number of somatic/psychiatric symptoms reported [15] , and an almost linear association exists between the number of nonmusculoskeletal symptoms and the number of pain sites [16] . In addition, the literature suggests that some somatic/psychiatric and psychiatric symptoms such as fatigue [9, [17] [18] [19] [20] , sleep problems [18, 19, 21] , nonorganic physical findings [10] . stiffness [22] , and depression [19, 23, 24] may be pain-determined, that is, they may improve or worsen, respectively, with decreases or increases in pain. The Grovle et al. study described above is another example of that concept. In that study, the sciatica population was followed for 1 year. At the end of 1 year, a fully recovered group was identified within the sciatica group. The prevalence of somatic/ psychiatric symptoms in the recovered group was then compared with prevalence in the general population group. The prevalence of subjective health complaints (headache, stomach discomfort, sleep problems, tiredness/fatigue, dizziness, anxiety, and depression) in the recovered sciatica group was no longer significantly greater vs the general population [13] . The possibility that pain may be associated with some somatic/psychiatric symptoms indicates that a nonpain general population group would make an ideal comparison group for these prevalence studies.
As described above, some studies have compared the prevalence of somatic/psychiatric symptoms in CPPs with that in the general population. However, no previous studies have compared the prevalence of somatic/ psychiatric symptoms in acute pain patients (APPs) vs the general population and vs CPPs. As such, the objectives of this study are to compare the prevalence of 15 symptoms (somatic, psychiatric) within community nonpatients without pain (CNPWPs) with that in APPs and CPPs and to compare the prevalence of these symptoms between APPs and CPPs. As some somatic/psychiatric symptoms may be pain-determined [9, 10, [17] [18] [19] [20] [21] [22] [23] [24] , the following hypotheses were formulated for this study:
1. APPs and CPPs should affirm a greater number of somatic/psychiatric symptoms vs CNPWPs, as both APPs and CPPs have pain while CNPWPs do not. 2. APPs should affirm somatic/psychiatric symptoms at the same frequency as CPPs, as both have pain. 3. Somatic/psychiatric symptoms in APPs and CPPs should be significantly intercorrelated. We hypothesize this relationship because the literature suggests that depression risk is increased in the manner of a dose-response relationship by a number of somatic symptoms [25] .
Methods

Subjects/Participants
This is a study using a data pool of 600 items/questions previously utilized to develop the Battery for Health Improvement 2 (BHI 2). The BHI 2 is made up of a subset of items from this data pool [26] ; it is a behavioral inventory designed to measure various psychiatric, psychological, and somatic problems usually associated with chronic pain. The present study did not utilize the BHI 2 scales in any way in the analyses and was not done to develop additional scales for the BHI 2 or to validate BHI 2 scales. The present study deals with 15 items from this data pool, representing somatic/psychiatric symptoms frequently identified in the pain literature as being associated with chronic pain and being frequent CPP complaints: 1) fatigue; 2) numbness or tingling in an extremity; 3) dizziness; 4) difficulty opening/closing mouth; 5) sudden muscle weakness; 6) difficulty staying asleep; 7) depression; 8) muscle tightness; 9) nervousness; 10) irritability; 11) memory problems; 12) falling because legs give way; 13) nausea; 14) difficulty concentrating; and 15) headaches. Symptoms were selected for testing from the data pool if there was previous literature that had indicated they might be associated with chronic pain. For example, difficulty opening/closing mouth was included because this is a common symptom in temporomandibular disorder, which in turn is frequently associated with chronic pain states such as fibromyalgia [4] .
A total number of 2,487 subjects/patients were administered the 600 data pool items in the original BHI 2 development study. Of these, 223 subjects/patients were eliminated from the original study for the following reasons: 1 subject did not sign the informed consent form; 41 subjects had missing age or gender or had listed contradictory ages or genders; and 57 subjects were eliminated because they failed to complete the assigned forms. Also, while all subjects were administered the data pool items from which the BHI 2 validity scales were scored, some subjects were also administered the Minnesota Multiphasic Personality Inventory-2 or Millon Clinical Multiaxial Inventory-III tests. If the subject had an invalid profile on any of these tests, he or she was eliminated from the original data pool. Overall, invalid profiles eliminated 124 subjects. This left 2,264 subjects/patients with complete information and valid responses to the 600 data pool items now making up the data pool/set. Thus, all of these subjects/patients (N = 2,264) had responded in a valid manner to the 600 data pool items. The current study is based on the information contained in this data pool.
Of the 2,264 subjects/patients, 777 came from rehabilitation facilities and were actually patients. The remaining 1,487 subjects came from the community and not from any medical facility. Of these 1,487 community subjects, 1,329 had responded "no" to the item "Do you have a serious medical condition?" and were designated as a community healthy group. One hundred fifty-eight responded with a "yes" to this item and were designated as the community nonhealthy group. The community subjects had been recruited from 16 states representing all the geographical regions of the United States. They were recruited by newspaper advertisements and posters; stratified according to race, education, age, and gender; and recruited to match these demographics. No subject was excluded on the basis of past or present medical or psychological diagnoses [26] . Of the designated community healthy group (N = 1,329), 129 had had no pain whatsoever in the previous month and were designated the CNPWP group, one of the groups of interest to this study.
The remaining 777 patients (2,264 minus 1,329 in the healthy group and 158 in the nonhealthy group) had been recruited from rehabilitation facilities where they were being treated for pain and functional problems. Of these 777 rehabilitation patients, 667 had pain (numerical rating scale [NRS] score greater than zero) and 110 had no pain. Of patients with pain, 341 were designated as having chronic pain (CPPs; pain equal to or greater than 90 days in duration). The remaining patients (N = 326) were designated as having acute pain (APPs; less than 90 days in duration). The CPP and APP groups are the other two groups of interest and, besides the CNPWP group, are the focus of the present study. A flowchart of how these groups were derived is presented in the Appendix.
Instrumentation
One of the data pool items was a horizontal 10-cm NRS scale anchored at 0 ("no pain or discomfort") and 10 ("worst pain or discomfort I can imagine having"). Using this scale and considering all of the pain-affected parts of the body, the subjects were asked to rate both the highest average and the lowest average pain experienced in the last month (two other items). Subjects were also asked about the length of time the pain was present.
The 600 individual data pool items are not an inventory and contain no scales; therefore, they have no associated reliability and validity data. However, each item had the following 1-week test-retest reliability scores for the 15 symptoms of interest to this study (each subject/patient completed the 600 questions twice; the results refer to the original questions): fatigue, r = 0.91; numbness or tingling in an extremity, r = 0.86; dizziness, r = 0.74; difficulty opening/closing mouth, r = 0.76; sudden muscle weakness, r = 0.68; difficulty staying asleep, r = 0.81; depression, r = 0.88; muscle tightness, r = 0.86; nervousness, r = 0.87; irritability, r = 0.87; memory problems, r = 0.83; falling because legs give way, r = 0.71; nausea, r = 0.81; difficulty concentrating, r = 0.87; and headaches (migraine, r = 0.94; tension, r = 0.88).
Data Collection Procedures
Participation was by self-selection; subjects were reimbursed ($60.00) for their participation. Any patient or subject was allowed to participate after passing the exclusion criteria of being less than 18 years or over 65 and not being able to read the data pool items. The over-65 age group was excluded because one of the BHI 2 scales being developed was job dissatisfaction, which would not be applicable to those who were retired. No subject/patient selected refused to participate. Data pool items were administered in a confidential manner (questionnaires were assigned a random ID number). No records were kept regarding which ID number a patient or nonpatient was assigned. Data were processed by persons having no contact with or knowledge of the respondents and were deidentified per Health Insurance Portability and Accountability Act requirements. All groups signed an informed consent form advising the subject/patient of the risks and benefits of participation. The consent form advised that the information would be used for research purposes pertaining to developing better methods for the assessment of medical patients, that no results or feedback would be given, and that the information gathered would not influence the course of their clinical care. The consent form was developed by an internal committee at Pearson Assessments whose function was to monitor the process of gathering information into the data pool at various sites. Pearson Assessments is a company that markets behavioral testing materials, including the BHI 2, and funded the study for the development of the BHI 2. Before use, the consent form had been sent out for approval to an external IRB (an institutional review board not within and not part of Pearson Assessments). The internal committee reported on information gathering and consent form implementation to the external IRB. The data pool set was presented in a deidentified format for BHI 2 development and, years later, for further analysis for this study.
Data Analysis
Response groups (affirmation vs nonaffirmation) to the data pool items were established as follows. Each item was scored on a four-point Likert scale in one of two formats. On some items, the available responses were "strongly disagree," "disagree," "agree," and "strongly agree" (assigned scores 0 through 3, respectively). For the analyses described below, these items were transformed into a dichotomy where participants were classified as being in the affirmative if they agreed or strongly agreed and therefore could be considered to have the symptom. On other items, the available responses were "not a problem," "small problem," "moderate problem," and "big problem" (assigned scores 0 through 3, respectively). These items were also transformed into a dichotomy where participants were classified as reporting a somatic complaint if they characterized it as a small, moderate, or big problem, thereby confirming that they had the symptom. We decided to dichotomize the variables because we were interested in demonstrating whether symptoms were present/not present, as this issue is important clinically for treatment. Also, our scales were such that they enabled us to clearly identify whether the subject/patient did or did not have the symptom. In addition, dichotomizing allowed us to use logistic regression, which in turn allowed us to analyze both continuous and dichotomous variables.
Data were managed and analyzed using SPSS 19 (IBM, Armonk, NY, USA) and SAS 9.1.3 (SAS Institute, Cary, NC, USA) software. Frequency and descriptive statistics were calculated to check all relevant characteristics of the data for each group.
Chi-squares were calculated for the 15 somatic/ psychiatric symptoms, with the CNPWPs (N = 129) as the comparison group vs APPs (N = 326) and CPPs (N = 341). Chi-squares were also calculated for the 15 somatic/psychiatric symptoms, with the APPs as the comparison group vs CPPs. Then, we performed hierarchical logistic regression analyses for each individual somatic/psychiatric symptom, comparing CNPWPs with APPs and CPPs while controlling for age, sex, and level of pain and comparing APPs and CPPs whilr controlling for age, sex, and level of pain. Next, we performed a Spearman's rho correlation analysis among the 15 symptoms for APPs and CPPs. We denoted whether the relationship was strong (P > 0.5) or of moderate strength (P between 0.3 and 0.5). We then calculated the total number of somatic/psychiatric symptoms that were correlated at a moderate or strong correlation with each individual somatic/psychiatric symptom for both APPs and CPPs (see Table 1 ).
Duration of pain could theoretically have an impact on whether a somatic symptom would/would not be present.
As such, we performed a set of logistic regression analyses for each somatic/psychiatric symptom in both APPs and CPPs in order to determine if time in pain in days predicted the presence/absence of that symptom.
After evaluating the influence of gender, age, and pain level in each model, we only considered a finding to be significant at P ≤ 0.01 because of the potentially large number of items that could be entered into the analyses. We wanted to ensure that our Type I error rate was minimized as much as possible and to rule out spurious findings in the results. Thus, we only reported significant findings. Table 2 displays prevalence (percentages) for the 15 somatic/psychiatric symptoms for CNPWP vs APPs and CPPs, respectively. For the two sets of logistic regressions, the final model chi-square comparisons are reported after controlling for age, sex, and level of pain. For the first set of comparisons, APPs had a significantly (P < 0.01) higher affirmation rate than CNPWPs on 11 symptoms: fatigue, numbness or tingling, dizziness, sudden paralysis or muscle weakness, muscle tightness, nervousness, irritability, falling because legs give way, nausea, difficulty concentrating, and migraine or tension headaches. For the second set of comparisons, CPPs had a significantly (P < 0.01) higher affirmation rate than the CNPWPs on 13 symptoms: fatigue, numbness or tingling, dizziness, sudden paralysis or muscle weakness, difficulty staying asleep (note that the sleeping item was given as "no difficulty staying asleep" and scored in the reverse direction), muscle tightness, nervousness, irritability, memory problems, falling because legs give way, nausea, difficulty concentrating, and migraine or tension headaches. Thus, as hypothesized (hypothesis 1), CNPWPs reported the presence of fewer somatic/ psychiatric symptoms compared with APPs and CPPs. CPPs reported a significantly (P < 0.01) higher affirmation rate than APPs on 8 symptoms: numbness or tingling, sudden paralysis or muscle weakness, difficulty staying asleep (given as "no difficulty staying asleep" and scored in the reverse direction), muscle tightness, memory problems, falling because legs give way, nausea, and difficulty concentrating. These findings did not conform to hypothesis 2.
Results
To save space, the Spearman's rho correlation tables for the 15 somatic/psychiatric symptoms for APPs and CPPs are not presented here but are available upon request. A correlation from those tables was considered to be notable if it was moderate (P between 0.3 and 0.5) or strong (P > 0.5). For the APPs, the symptoms were typically closely related to each other. The following correlations were found to be strong ( Table 1 displays the total number of moderate and strong correlations for each somatic/psychiatric symptom for both APPs and CPPs. These findings conformed with hypothesis 3. P value, odds ratio, and lower and upper 95% confidence limits for the odds ratio for each of the four predictor variables) for each of the 15 clinical symptoms in APPs. Every overall model was statistically significant, except for being unable to open or close the mouth. After evaluating gender, age, and pain level, days in pain did not statistically predict any of the symptoms in APPs (P < 0.01 was the required level of significance; see Table 4 ). , degrees of freedom, P value, and percentage of cases correctly classified for the overall model predicted by gender, age, pain level, and days in pain (with the coefficient estimate, Wald P value, odds ratio, and lower and upper 95% confidence for the odds ratio for each of the four predictor variables) for each of the 15 clinical symptoms in CPPs. Every overall model was statistically significant, except for fatigue, dizziness, being unable to open or close mouth, difficulty staying asleep, depression, nervousness, irritability, memory problems, and difficulty concentrating. After evaluating gender, age, and pain level, days in pain did not statistically predict any of the symptoms in CPPs (P < 0.01 was the required level of significance; see Table 5 ).
Discussion
To our knowledge, this is the first study of its kind in the literature. As noted in the introduction, we formulated a number of hypotheses for the results of this study in reference to CPPs and APPs. The first hypothesis was that APPs and CPPs should affirm a greater number of the 15 somatic/psychiatric symptoms at a 0.01 level of significance than CNPWPs. This was indeed the case. Controlling for age, gender, and pain, APPs were more likely than CNPWPs to affirm 11 of the 15 symptoms. Similarly, controlling for age, gender, and pain, CPPs were more likely than CNPWPs to affirm 13 out of the 15 symptoms.
The second hypothesis was that APPs and CPPs should affirm symptoms at the same frequency as, according to previous literature, some of these symptoms may be paindetermined [3, 9, 10, 17, 18, [21] [22] [23] [24] . However, this was not the case. Controlling for age, gender, and pain, CPPs were more likely than APPs to affirm 8 out of the 15 symptoms at a 0.01 level: numbness/tingling, sudden paralysis or muscle weakness, difficulty staying asleep, muscle tightness, memory problems, falling because legs give way, nausea, and difficulty concentrating. This indicated that other issues besides pain level might be associated with the presence of somatic/psychiatric symptoms in CPPs. One of these could be length of time in pain. This is the reason why we performed the sets of logistic regressions for APPs and CPPs-to predict each individual somatic symptom. However, after evaluating age, gender, and pain level, days in pain did not statistically predict any symptom (at the required level of significance of P < 0.01) in either APPs or CPPs. As such, it can be concluded that time in pain was not one of the reasons why CPPs had a greater prevalence of some symptoms than APPs. One other possibility for this difference was psychiatric pathology. This possibility is discussed below under potential confounders.
The third hypothesis was that we would find significant intercorrelations among symptoms in both APPs and CPPs. This was indeed the case. As presented in Table 1 , in APPs, the minimum number of other symptoms that an individual symptom correlated with at a moderate or strong level was 1, and the maximum was 11. In CPPs, the minimum number was 0 and the maximum number was 4. Thus, it appears that in APPs, symptoms had a greater degree of intercorrelation variability than in CPPs. In addition, for each individual symptom, APPs demonstrated more intercorrelation than CPPs (see Table 1 ). This is a new finding and will need replication. The fact that the numbers of moderate and strong intercorrelations differed for APPs and CPPs supports the idea that APPs and CPPs are different in terms of how somatic/psychiatric symptoms congregate with each other in these patients. These intercorrelation results are also interesting for another reason. The cancer pain literature has presented significant evidence that in cancer patients, some somatic/psychiatric symptoms may cluster together, and has identified one symptom cluster: pain/fatigue/ insomnia/depression [27] [28] [29] . A symptom cluster is defined as two or more concurrent symptoms related to each other, such that an increment in one symptom is associated with an increment or decrement in another symptom [27] [28] [29] . Whether symptoms form a cluster can be determined by shared variance analyses, cluster analyses, and moderation analyses. The fact that some of the somatic/psychiatric symptoms in our analysis were moderately or strongly intercorrelated could indicate that some of these symptoms could cluster together. This was actually the case. We performed a cluster analysis on these 15 symptoms in APPs and CPPs. There were 4 symptom clusters for APPs and 5 for CPPs. For CPPs, the clusters represented memory and neurological, behavioral, somatic, and autonomic problems. CPPs with moderate and severe pain had three and four symptom clusters, respectively, and differed in symptom cluster constitution [30] . The concept of symptom clusters is important clinically because, as pointed out above, treatment improvement in one symptom in a cluster may result in improvement in other symptoms in the cluster [27, 28, 31] .
Our results indicated that some somatic/psychiatric symptoms such as memory problems, neurological symptoms, sleep, and the like are more commonly found in CPPs vs our comparison groups. At issue is whether there is previous literature that supports these findings. Memory problems are a prominent FMS patient complaint [32] and are also commonly present in other CPPs [21, 33] . These patients have been shown to have neuropsychological deficits similar to those of patients with mild cognitive impairment [34] . In addition, these cognitive deficits may be pain-related [35] and may even be specifically related to the level of pain [36] . Neurological symptoms (poor balance, weakness, tingling, numbness, etc.) are often a prominent complaint in FMS [31, 37] and other CPPs [38] . Poor sleep as a somatic complaint, not necessarily related to depression, is also frequently found in CPPs [39] . All of these symptoms were more prevalent in our CPPs to a significantly greater degree than in APPs and CNPWPs. Overall, it appears that the previous literature indirectly supports our finding for some somatic/psychiatric symptoms.
What is the potential clinical utility of our findings? First, studies have demonstrated that a small group of chronic physical conditions (diagnoses) are independently associated with chronic pain: arthritis, neck/back disorders, heart disease, migraine, and bowel disease [40] . Some of the somatic/psychiatric symptoms in our study are physical complaints related to these disease states, for instance headaches. Thus, somatic/psychiatric symptoms associated with pain are important, as they may represent a disease entity, and should be considered red flags. However, clinically, the most important consequence of our findings is that pain clinicians should approach every APP and CPP with the understanding that these patients are likely to demonstrate a great number of somatic/ psychiatric symptoms beyond those of difficulty sleeping, fatigue, depression, and anxiety.
Second, as noted in the introduction, comorbidity can complicate, interfere with, or increase the difficulty of the treatment of the index disease [1] . Although not tested in this study, the presence of somatic/psychiatric symptoms in chronic pain should then make the treatment of that patient more difficult. There is also a lack of consensus as to how to treat patients with multiple comorbid symptoms [41] . This increases the difficulty for the pain clinician in dealing with these patients. However, some data in the literature point to possible approaches to these patients. Some evidence from the rheumatology literature suggests that decreasing disease activity may improve some somatic/psychiatric symptoms [42] . In other CPPs, many somatic/psychiatric symptoms could be pain-determined and appear to improve and worsen according to pain level [8] [9] [10] 13, 16, 22, 24] . Additionally, some somatic/ psychiatric symptoms (e.g., sleep [21] or fatigue [17] or stiffness/tight muscles [22] ) improve with successful pain treatment even when that treatment is in no way directed at the somatic/psychiatric symptoms. Overall, this type of evidence indirectly suggests that effective pain treatment may act to reduce the level of somatic/psychiatric symptoms. As such, this literature would suggest that pain clinicians could improve some somatic/psychiatric symptoms through pain management such as physical therapy [43] . Conversely, as this evidence is correlational and does not indicate the direction of causality, it also suggests that treating a somatic/psychiatric symptom, such as insomnia, may act to reduce pain and fatigue [44, 45] . However, it is to be noted that the data in the present study do not address or support any of these possibilities.
What are the psychophysiological mechanisms behind this relationship between somatic/psychiatric symptoms and the presence of pain? Presently, we do not fully understand this relationship. However, some preliminary data have shed some light on these potential psychophysiological mechanisms. For depression, the relationship with pain may be the result of the close association of the neurological circuits for emotions and pain in the nervous system [13] . These circuits for sensory and affective pain processing are thought to be parallel but independent of each other [46] . Another possible hypothesis is that this relationship could be mediated by the cytokine system. A very recent study [47] has demonstrated an association between pro-and anti-inflammatory cytokine genes and the symptom cluster of pain, fatigue, sleep disturbance, and depression. For memory, there is evidence from acute pain induction studies that working memory is somehow affected by pain [23] . For neurological symptoms, there is some evidence that suggests pain might inhibit muscle activation, thereby prompting weakness and increasing fatigue [39] .
The results of our study are hindered by several potential confounders. First, it is possible that some of the APPs and CPPs gave invalid, exaggerated, or random information about somatic/psychiatric symptoms. However, patients/subjects demonstrating invalid profiles on psychological testing were eliminated from the data pool. Thus, this potential confounder is unlikely to have occurred, but remains a possibility. Second, self-selection bias for entrance into the data pool is possible. As noted in the Methods section, the 777 rehabilitation patients were recruited from various clinics by posters/flyers and were paid for their participation. Similarly, community nonpatients were also recruited by newspaper advertisements and posters. Thus, this issue could have served as a potential confounder to the results of this study. Third, the defining criterion for the distinction between acute and chronic pain utilized in this study was pain duration. This is well accepted in the pain literature. However, this does not mean that the condition is etiologically any different or that the patient knows that he/she has acute pain or chronic pain. Thus, the selection and comparison of these groups for analysis could be premature. However, the finding that CPPs were statistically more likely to affirm more somatic/psychiatric symptoms vs APPs even after controlling for age, sex, and level of pain would indicate that the artificial time distinction is tapping different populations of pain patients. Fourth, community subjects identified themselves as healthy/nonhealthy by answering the question "Do you have a serious medical condition?" Answering "yes" to this question eliminated subjects who were aware of having a serious medical condition from the perceived healthy group. However, this may have left subjects in the healthy group who were unaware of having a serious medical condition, along with those who had a serious medical condition but who did not perceive themselves as having such a condition, as well as those who did not have a serious medical condition. Serious medical conditions may or may not be associated with somatic/psychiatric symptoms. However, subjects who do not have a serious medical condition may also have somatic symptoms that may be associated with conditions not considered "serious." Somatic symptoms may also be present in subjects with no identified medical condition. Thus, our CNPWP group may have contained subjects unaware of their serious medical condition, subjects not perceiving themselves as having such a condition but in fact having one, and subjects with less-than-serious medical conditions producing somatic/psychiatric symptoms. As such, our CNPWP group does not necessarily represent truly "healthy" subjects. Consequently, the prevalence of somatic symptoms in our "healthy" group could have been greater than what a truly "healthy" group should exhibit. This then could have led to incorrect comparison results between our groups. However, as we demonstrated a greater prevalence of some somatic/psychiatric symptoms in APPs and CPPs vs CNPWPs, the potentially greater prevalence of somatic/psychiatric symptoms in the "healthy" group would not have made a difference to these results except to make them more meaningful. Fifth, the community subjects were collected randomly from the general population but were self-selected. They were then recruited to match the demographics of the general population of their state by race, education, age, and gender. Thus, the community group should be representative of the general population of its state of origin. But because the population was self-selected and was paid for its participation, it may not have been representative of the general population of that state in other ways besides race, education, age, and gender. Sixth, of the eight symptoms that were more commonly found in CPPs vs APPs, some of them were neurological: numbness/tingling, sudden paralysis or muscle weakness, muscle tightness, and falling because legs give way. As such, a possible explanation for this finding is the likelihood that APPs had fewer patients who were neurologically involved. Our APPs and CPPs were not matched for neurological diagnoses, as these data were not available to us. Thus, this possibility served as a potential confounder to the results of this study and will have to be pursued in future studies. Finally, it is well known that CPPs have significant psychiatric comorbidity [2] . However, to our knowledge, there are no data on psychiatric comorbidity in APPs, and APPs have never been compared for psychiatric comorbidity with CPPs. It is, therefore, unknown whether APPs have more, the same, or less psychiatric comorbidity than CPPs normally. If our APP group was selected in such a way that it differed from the normal distribution of psychiatric pathology among APPs, this could then lead to potential confounding of our results. Depression and anxiety are some of the most common comorbidities noted in CPPs [2] . Interestingly, however, symptoms representing these two problems were not overrepresented in CPPs vs APPs (see Table 3 ). In addition, other symptoms that could be representative of other emotional problems (fatigue, dizziness, irritability) were also not overrepresented in CPPs vs APPs (see Table 3 ). As such, our results indicated that the distribution of psychiatric pathology could be similar in APPs vs CPPs. However, this result could be simply due to confounding. In addition, symptoms do not necessarily represent psychiatric diagnoses. As such, our results are not necessarily representative of psychiatric pathology. Thus, this issue will require further study.
Conclusion
CPPs and APPs affirmed a greater prevalence of somatic/ psychiatric symptom comorbidities than CNPWPs. CPPs in turn affirmed a greater prevalence of somatic/ psychiatric symptoms vs APPs. These findings have implications for clinical practice and future research. 
